According to the research report, the global endocrine testing market size is expected to touch USD 12.8 Billion by 2032, from USD 5.45 Billion in 2022, growing with a significant CAGR of 8.92% from 2023 to 2032.
Key Takeaways:
- North America has accounted revenue share of around 46% in 2022.
- By End-user, the commercial laboratories segment captured more than 49% of revenue share in 2022.
- The hospital end-user segment has captured a revenue share of 35% in 2022.
- By Test Type, the human Chorionic Gonadotropin (hCG) hormone test segment dominated the market in 2022, the segment is expected to continue the trend during the forecast period.
- By Technology, the immunoassay segment dominated the market in 2022.
The endocrine testing report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global endocrine testing in conjunction with the geographical landscape of this vertical have also been included in this report.
The report offers intricate dynamics about different aspects of the global endocrine testing market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global endocrine testing during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.precedenceresearch.com/sample/3211
This study covers a detailed segmentation of the global endocrine testing market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global endocrine testing market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.
Key Players
- Abbott Laboratories
- bioMerieux SA
- Bio-Rad Laboratories Inc.
- DiaSorin S.p.A.
- F. Hoffmann-La Roche Ltd.
- AB Sciex
- Agilent Technologies Inc.
- Ortho Clinical Diagnostics
- Laboratory Corporation of America Holdings
- Quest Diagnostics Incorporated
Market Segmentation
By Test Type
- Estradiol (E2) Test
- Dehydroepiandrosterone Sulfate (DHEAS) Test
- Progesterone Test
- Testosterone Test
- Thyroid Stimulating Hormone (TSH) Test
- Prolactin Test
- Follicle Stimulating Hormone (FSH) Test
- Human Chorionic Gonadotropin (hCG) Hormone Test
- Luteinizing Hormone (LH) Test
- Cortisol Test
- Insulin Test
- Others
By Technology
- Immunoassay
- Chromatography
- Mass Spectroscopy
- Nucleic Acid Based
By End-User
- Hospitals
- Commercial Laboratories
- Ambulatory Care Centers
- Others
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Research Methodology
The research methodology adopted by analysts for compiling the global endocrine testing report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global endocrine testing market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Endocrine Testing Market
5.1. COVID-19 Landscape: Endocrine Testing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Endocrine Testing Market, By Test Type
8.1. Endocrine Testing Market, by Test Type, 2023-2032
8.1.1 Estradiol (E2) Test
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Dehydroepiandrosterone Sulfate (DHEAS) Test
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Progesterone Test
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Testosterone Test
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Thyroid Stimulating Hormone (TSH) Test
8.1.5.1. Market Revenue and Forecast (2020-2032)
8.1.6. Prolactin Test
8.1.6.1. Market Revenue and Forecast (2020-2032)
8.1.7. Follicle Stimulating Hormone (FSH) Test
8.1.7.1. Market Revenue and Forecast (2020-2032)
8.1.8. Human Chorionic Gonadotropin (hCG) Hormone Test
8.1.8.1. Market Revenue and Forecast (2020-2032)
8.1.9. Luteinizing Hormone (LH) Test
8.1.9.1. Market Revenue and Forecast (2020-2032)
8.1.10. Cortisol Test
8.1.10.1. Market Revenue and Forecast (2020-2032)
8.1.11. Insulin Test
8.1.11.1. Market Revenue and Forecast (2020-2032)
8.1.12. Others
8.1.12.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Endocrine Testing Market, By Technology
9.1. Endocrine Testing Market, by Technology, 2023-2032
9.1.1. Immunoassay
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Chromatography
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Mass Spectroscopy
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Nucleic Acid Based
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Endocrine Testing Market, By End-User
10.1. Endocrine Testing Market, by End-User, 2023-2032
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Commercial Laboratories
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Ambulatory Care Centers
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Endocrine Testing Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Test Type (2020-2032)
11.1.2. Market Revenue and Forecast, by Technology (2020-2032)
11.1.3. Market Revenue and Forecast, by End-User (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Test Type (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Technology (2020-2032)
11.1.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Test Type (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Technology (2020-2032)
11.1.5.3. Market Revenue and Forecast, by End-User (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Test Type (2020-2032)
11.2.2. Market Revenue and Forecast, by Technology (2020-2032)
11.2.3. Market Revenue and Forecast, by End-User (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Test Type (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Technology (2020-2032)
11.2.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Test Type (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Technology (2020-2032)
11.2.5.3. Market Revenue and Forecast, by End-User (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Test Type (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Technology (2020-2032)
11.2.6.3. Market Revenue and Forecast, by End-User (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Test Type (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Technology (2020-2032)
11.2.7.3. Market Revenue and Forecast, by End-User (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Test Type (2020-2032)
11.3.2. Market Revenue and Forecast, by Technology (2020-2032)
11.3.3. Market Revenue and Forecast, by End-User (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Test Type (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Technology (2020-2032)
11.3.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Test Type (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Technology (2020-2032)
11.3.5.3. Market Revenue and Forecast, by End-User (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Test Type (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Technology (2020-2032)
11.3.6.3. Market Revenue and Forecast, by End-User (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Test Type (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Technology (2020-2032)
11.3.7.3. Market Revenue and Forecast, by End-User (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Test Type (2020-2032)
11.4.2. Market Revenue and Forecast, by Technology (2020-2032)
11.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Test Type (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Technology (2020-2032)
11.4.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Test Type (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Technology (2020-2032)
11.4.5.3. Market Revenue and Forecast, by End-User (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Test Type (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Technology (2020-2032)
11.4.6.3. Market Revenue and Forecast, by End-User (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Test Type (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Technology (2020-2032)
11.4.7.3. Market Revenue and Forecast, by End-User (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Test Type (2020-2032)
11.5.2. Market Revenue and Forecast, by Technology (2020-2032)
11.5.3. Market Revenue and Forecast, by End-User (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Test Type (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Technology (2020-2032)
11.5.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Test Type (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Technology (2020-2032)
11.5.5.3. Market Revenue and Forecast, by End-User (2020-2032)
Chapter 12. Company Profiles
12.1. Abbott Laboratories
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. bioMerieux SA
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Bio-Rad Laboratories Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. DiaSorin S.p.A.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. F. Hoffmann-La Roche Ltd.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. AB Sciex
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Agilent Technologies Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Ortho Clinical Diagnostics
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Laboratory Corporation of America Holdings
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Quest Diagnostics Incorporated
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments